Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer Statistics (2021) CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654

Gillen S, Schuster T, Meyer ZBC, Friess H, Kleeff J (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. 2010-04-20. 7(4):e1000267

Kamisawa T, Wood LD, Itoi T, Takaori K (2016) Pancreatic cancer. Lancet 388(10039):73–85

Article  CAS  PubMed  Google Scholar 

Kato T, Matsuo Y, Ueda G, Murase H, Aoyama Y, Omi K et al (2022) Enhanced CXCL12/CXCR4 signaling increases tumor progression in radiationresistant pancreatic cancer. 2022-04-01.;47(4)

Hidalgo M (2010) Pancreatic cancer. 2010-04-29.;362(17):1605-17

Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL et al (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. 2012-11-15. 491(7424):399–405

Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897):1801–1806

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A et al (2019) Real-time targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. 2019-06-01. 156(8):2242–53e4

Lal G, Liu G, Schmocker B, Kaurah P, Ozcelik H, Narod SA et al (2000) Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 60(2):409–416

CAS  PubMed  Google Scholar 

Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML et al (2012) ATM mutations in patients with hereditary pancreatic cancer. 2012-01-01. 2(1):41–46

Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW et al (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324(5924):217

Article  CAS  PubMed  PubMed Central  Google Scholar 

Resta N, Pierannunzio D, Lenato GM, Stella A, Capocaccia R, Bagnulo R et al (2013) Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study. 2013-07-01. 45(7):606–611

Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP et al (2012) Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. 2012-03-20. 30(9):958–964

Chaffee KG, Oberg AL, McWilliams RR, Majithia N, Allen BA, Kidd J et al (2018) Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. 2018-01-01. 20(1):119–127

Kowalewski A, Szylberg L, Saganek M, Napiontek W, Antosik P, Grzanka D (2018) Emerging strategies in BRCA-positive pancreatic cancer. 2018-08-01. 144(8):1503–1507

Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F et al (2016) Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice guidelines for cancer prevention and screening. 2016-09-01. 27(suppl 5):v103–v10

Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (2011) Pancreatic cancer. Lancet 378(9791):607–620

Article  PubMed  PubMed Central  Google Scholar 

Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B et al (2003) BRCA2 germline mutations in familial pancreatic carcinoma. 2003-02-05. 95(3):214–221

Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R et al (2002) Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 62(13):3789–3793

CAS  PubMed  Google Scholar 

Petersen GM (2016) Familial pancreatic cancer. 2016-10-01. 43(5):548–553

Kate Y (2019) PARP Inhibitors in Pancreatic Cancer. https://www.cancertodaymagorg/Pages/cancer-talk/PARP-Inhibitors-in-Pancreatic-Canceraspx

Rombouts SJ, Vogel JA, van Santvoort HC, van Lienden KP, van Hillegersberg R, Busch OR et al (2015) Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. 2015-02-01. 102(3):182–193

Li Q, Tian Y, Yang D, Liang Y, Cheng X, Gai B (2019) Permanent Iodine-125 seed implantation for the treatment of Nonresectable Retroperitoneal Malignant tumors. 18:1533033819825845 2019-01-01

Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G (2017) Immunogenic cell death in cancer and infectious disease. 2017-02-01. 17(2):97–111

Inoue H, Tani K (2014) Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ 21(1):39–49

Article  CAS  PubMed  Google Scholar 

Kepp O, Tesniere A, Zitvogel L, Kroemer G (2009) The immunogenicity of tumor cell death. 2009-01-01. 21(1):71–76

Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L et al (2009) Chemotherapy induces ATP release from tumor cells. 2009-11-15. 8(22):3723–3728

Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P et al (2007) Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 14(10):1848–1850

Article  CAS  PubMed  Google Scholar 

Walsh SR, Simovic B, Chen L, Bastin D, Nguyen A, Stephenson K et al (2019) Endogenous T cells prevent tumor immune escape following adoptive T cell therapy. 2019-12-02. 129(12):5400–5410

Su X, Wang Z, Duan S (2023) Targeted drug delivery systems for pancreatic ductal adenocarcinoma: overcoming tumor microenvironment challenges with CAF-specific nanoparticles. J Natl Cancer Cent 3(4):306–309. https://doi.org/10.1016/j.jncc.2023.10.001

Article  Google Scholar 

Halytskiy VA (2019) MiRNA deregulation can contribute to breakdown of MHC I class antigen processing and presenting machinery in breast cancer cells. Res Notes 110:S19

Google Scholar 

Boesen M, Svane IM, Engel AM, Rygaard J, Thomsen AR, Werdelin O (2000) CD8 + T cells are crucial for the ability of congenic normal mice to reject highly immunogenic sarcomas induced in nude mice with 3-methylcholanthrene. 2000-08-01. 121(2):210–215

Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. 2013-10-01. 14(10):1014–1022

Wieczorek M, Abualrous ET, Sticht J, Alvaro-Benito M, Stolzenberg S, Noe F et al (2017) Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in Antigen Presentation. 8:292 2017-01-20

Wang D, Shi Y, Wang Z, Zhang J, Wang L, Hongyu MA et al (2024) Meiotic nuclear divisions 1 suppresses the proliferation and invasion of pancreatic cancer cells via regulating H2A.X variant histone. BIOCELL 48(1):111–122

Article  Google Scholar 

Kim HS, Lee YS, Dong SM, Kim HJ, Lee DE, Kang HW et al (2024) Neural Wiskott-Aldrich syndrome protein(N-WASP)promotes distant metastasis in pancreatic ductal adenocarcinoma via activation of LOXL2. Oncol Res 32(4):615–624

Article  PubMed  PubMed Central  Google Scholar 

Woo SR, Corrales L, Gajewski TF (2015) The STING pathway and the T cell-inflamed tumor microenvironment. 2015-04-01. 36(4):250–256

Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A et al (2014) STING-Dependent cytosolic DNA sensing promotes Radiation-Induced type I Interferon-Dependent Antitumor immunity in immunogenic tumors. Immunity 41(5):843–852

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY et al (2014) STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41(5):830–842

Article  CAS  PubMed  PubMed Central  Google Scholar 

Corrales L, Gajewski TF (2015) Molecular pathways: targeting the stimulator of Interferon genes (STING) in the Immunotherapy of Cancer. Clin Cancer Res 21(21):4774–4779

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marcus A, Mao AJ, Lensink-Vasan M, Wang L, Vance RE, Raulet DH (2018) Tumor-derived cGAMP triggers a STING-Mediated Interferon response in non-tumor cells to activate the NK Cell response. Immunity 49(4):754–63e4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nicolai CJ, Wolf N, Chang IC, Kirn G, Marcus A, Ndubaku CO et al (2020) NK cells mediate clearance of CD8(+) T cell-resistant tumors in response to STING agonists. 2020-03-20. 5(45):eaaz2738